214 related articles for article (PubMed ID: 18945481)
1. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes.
Sahli D; Eriksson JW; Boman K; Svensson MK
Thromb Res; 2009 Mar; 123(5):701-6. PubMed ID: 18945481
[TBL] [Abstract][Full Text] [Related]
2. Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up.
Rautio A; Boman K; Eriksson JW; Svensson MK
Diab Vasc Dis Res; 2016 May; 13(3):183-91. PubMed ID: 26818227
[TBL] [Abstract][Full Text] [Related]
3. Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
Deepa R; Velmurugan K; Saravanan G; Dwarakanath V; Agarwal S; Mohan V
J Assoc Physicians India; 2002 Jul; 50():901-6. PubMed ID: 12126344
[TBL] [Abstract][Full Text] [Related]
4. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
Mansfield MW; Catto AJ; Carter AM; Grant PJ
Diabet Med; 1998 Nov; 15(11):953-7. PubMed ID: 9827850
[TBL] [Abstract][Full Text] [Related]
6. Relationship of oxidative stress and fibrinolysis in diabetes mellitus.
Skrha J; Hodinár A; Kvasnicka J; Hilgertová J
Diabet Med; 1996 Sep; 13(9):800-5. PubMed ID: 8891455
[TBL] [Abstract][Full Text] [Related]
7. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
[TBL] [Abstract][Full Text] [Related]
8. [Association between serum uric acid level and peripheral vascular disease of lower extremities in type 2 diabetes mellitus subjects].
Zhang L; Zhou J; Li Q; Yu HY; Li M; Zhang F; Bao YQ; Jia WP
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):653-7. PubMed ID: 20450721
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
Brazionis L; Rowley K; Jenkins A; Itsiopoulos C; O'Dea K
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):786-91. PubMed ID: 18239151
[TBL] [Abstract][Full Text] [Related]
10. [Relationship of lipoprotein(a) to fibrinolytic activities in healthy subjects].
Xiong X; Zhao S; Wang Z; Lo L; Huang Q
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):555-7. PubMed ID: 10806767
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
12. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels.
Tan KT; Tayebjee MH; Lim HS; Lip GY
Diabet Med; 2005 Dec; 22(12):1657-62. PubMed ID: 16401308
[TBL] [Abstract][Full Text] [Related]
13. Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm.
Wanhainen A; Nilsson TK; Bergqvist D; Boman K; Björck M
J Vasc Surg; 2007 Jun; 45(6):1109-13. PubMed ID: 17543671
[TBL] [Abstract][Full Text] [Related]
14. A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients.
Testa R; Bonfigli AR; Sirolla C; Pieri C; Marra M; Antonicelli R; Manfrini S; Compagnucci P; Testa I
Diabetes Nutr Metab; 1999 Dec; 12(6):400-6. PubMed ID: 10782561
[TBL] [Abstract][Full Text] [Related]
15. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
[TBL] [Abstract][Full Text] [Related]
16. [Relationship of age, sex, body weight, smoking, blood lipids and fibrinolytic activities in healthy subjects].
Xiong X; Wang Z; Zhao S
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):65-7. PubMed ID: 11938745
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic activity in Chinese patients with diabetes or hyperlipidemia in comparison with healthy controls.
Ho CH; Jap TS
Thromb Haemost; 1991 Jan; 65(1):3-6. PubMed ID: 1902595
[TBL] [Abstract][Full Text] [Related]
18. Low level of tissue plasminogen activator activity in non-diabetic patients with a first myocardial infarction.
Lundblad D; Dinesen B; Rautio A; Røder ME; Eliasson M
J Intern Med; 2005 Jul; 258(1):13-20. PubMed ID: 15953128
[TBL] [Abstract][Full Text] [Related]
19. [Tissue plasminogen activator and diabetes mellitus].
Galajda P; Martinka E; Kubisz P; Mokán M
Vnitr Lek; 1998 Nov; 44(11):661-4. PubMed ID: 10422507
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein (a) as a determinant of arterial stiffness in elderly patients with type 2 diabetes mellitus.
Wakabayashi I; Masuda H
Clin Chim Acta; 2006 Nov; 373(1-2):127-31. PubMed ID: 16820145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
